Evolus CFO Sandra Beaver Announces Resignation

Evolus ( (EOLS) ) has issued an update.

On May 27, 2025, Evolus, Inc. announced the voluntary resignation of its Chief Financial Officer, Sandra Beaver, effective June 13, 2025, as she moves to a new opportunity in a private mental health and wellness technology company. The company emphasized that her departure was not due to any disagreements related to its operations or financial practices. CEO David Moatazedi acknowledged Beaver’s contributions to Evolus’ growth and success, noting the company’s strong momentum with recent product launches and record revenues. Evolus has initiated a search for her successor while its experienced finance team ensures a smooth transition.

The most recent analyst rating on (EOLS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.

Spark’s Take on EOLS Stock

According to Spark, TipRanks’ AI Analyst, EOLS is a Neutral.

Evolus’ overall score reflects strong revenue growth and strategic initiatives, such as securing a new credit facility, which are positive factors. However, the company’s ongoing financial instability, bearish technical indicators, and unattractive valuation considerably weigh down the score.

To see Spark’s full report on EOLS stock, click here.

More about Evolus

Evolus, Inc. is a global performance beauty company that focuses on redefining the aesthetic injectable market for beauty consumers through a customer-centric business model and innovative digital platform. Its flagship products include Jeuveau®, a neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of injectable hyaluronic acid gels.

Average Trading Volume: 933,875

Technical Sentiment Signal: Sell

Current Market Cap: $624.1M

See more data about EOLS stock on TipRanks’ Stock Analysis page.